Lionel Messi 'has been in secret talks with Inter Miami for... 'Completely false, wrong and utter RUBBISH': BBC commentator... Blackburn 'plan to keep Ben Brereton Diaz in the January... Arsenal 'offer a new deal' to William Saliba, with the... Mum-of-three struggling for months to find a rental home... Read the 'nasty' note left by a neighbour on homeowner's... Aussie who saved $200k by age 26 shares the money tricks he... The rise of 'quiet firing': The concerning and 'dangerous'...

If you adored this article and also you would like to receive more info concerning เช่ารถสงขลา i implore you to visit our web-page. Conte - whose current deal runs out at the end of the season but includes an option for the club to extend it by a year - helped guide Spurs back into the top four last year after taking charge in November. They sit third in the Premier League - just three points behind Manchester City - and are close to booking their spot in the Champions League round of 16, ensuring they get a result away at Marseille on Tuesday. "This is much higher than our assumption of $50 per shot and even assuming $80 per shot net price in high-income countries, we see $2 per share upside to our estimates" from the new prices, he wrote in a research note.

The launches include the Euclid space telescope and the Hera probe, a follow-up mission to NASA's DART spacecraft which last month succeeded in altering the path of a moonlet in the first test of a future planetary defense system. "We expect Moderna to adapt to this signal, and expect the mRNA duopolists, along with Novavax, to continue pricing in a similar range for the foreseeable future," SVB Securities David Risinger said in a research note. The drugmaker, which developed and sells the vaccine with Germany's BioNTech said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year.

BENGALURU, Oct 21 (Reuters) - Indian IT solutions provider Mphasis has a reasonable proportion of large contracts in its pipeline and expects its current trend of new deal wins to continue over the medium term, despite macro headwinds, a top company official said on Friday. Mphasis, early on Friday, reported second-quarter profit rose nearly 23% to 4.18 billion Indian rupees ($50.6 million), while revenue from operations increased 22.7% to 35.2 billion rupees, boosted by the deal wins.